Cat. No. 3915
Chemical Name: 5-(2,6-Dichlorophenyl)-2-[2,4-diflu
Biological ActivityHighly potent and selective p38α inhibitor (IC50 = 10 nM). Also blocks TNFα production in LPS-stimulated HWB in vitro (IC50 = 177 nM). Displays 1000-fold selectivity over closely related kinases, including ERK1, MK2 and JNK1-3.
External Portal InformationChemicalprobes.org is a portal that offers independent guidance on the selection and/or application of small molecules for research. The use of VX 745 is reviewed on the chemical probes website.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
Duffy et al (2011) The discovery of VX-745: a novel and selective p38α kinase inhibitor. ACS Med.Chem.Lett. 2 758.
Goldstein et al (2010) Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. J.Med.Chem. 53 2345. PMID: 19950901.
Bagley et al (2007) Rapid synthesis of VX-745: p38 MAP kinase inhibition in Werner syndrome cells. Bioorg.Med.Chem.Lett. 17 5107. PMID: 17659871.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for VX 745 include:
Haas et al (2013) The inflammatory kinase MAP4K4 promotes reactivation of Kaposi's sarcoma herpesvirus and enhances the invasiveness of infected endothelial cells. PLoS Pathog 9 e1003737. PMID: 24244164.
Do you know of a great paper that uses VX 745 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: VX 745, supplier, VX745, p38a, p38alpha, p38α, MAPK, inhibitors, inhibits, selective, potent, Tocris Bioscience, p38 MAPK Inhibitor products
Find multiple products by catalog number
New Products in this Area
Selective p38α/β inhibitor; orally bioavailableAX 15836
Potent and selective ERK5 inhibitor
April 22 - 26, 2017
Chicago, IL, USA